Prescription Drug Patent Licensing Act

Prescription Drug Patent Licensing Act - Requires that whenever the Federal Trade Commission, upon complaint made to it by a qualified applicant for a license under a drug patent, determines through an investigation and hearing that such application for license was not granted and that the price quoted to druggists by the patentee is more than 500 percent of the total cost of production, the Commission shall order the patentee to grant an unrestricted license to any qualified applicant to make, use, and sell such drug. States that the Commission may delay such order up to five years to provide a fair return on the patentee's invested capital. (Adds 35 U.S.C. 294)